Pharma Industry Shaken: New Leadership and Tariff Challenges

Novo Nordisk's newly appointed CEO, Maziar Mike Doustdar, steps into his role amid concerns over stagnating sales growth and a declining share price. Doustdar's priority will be to regain investor confidence and navigate rising competition in the weight-loss drug sector.

AstraZeneca's CEO recently announced plans for price reductions across their U.S. drug portfolio, aligning with a substantial $50 billion investment aimed at expansion. This comes as the Trump administration pressures pharmaceutical companies to lower medication costs.

In the pharmaceutical landscape, Italian company Recordati experienced a 9.6% increase in core profits this year, although it faces intensified challenges from foreign exchange rate fluctuations. Concurrently, Agilent Technologies plans to double its investments in India, projecting significant growth prospects in the market.

(With inputs from agencies.)